PGR and breast carcinoma: TNBCs are characterized by their lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and thus are not candidates for existing therapies that target ER, PR, or HER2 in breast cancer (3).